ArticleFrontiers in genetics2026
Application of chromosomal microarray analysis for prenatal diagnosis in 315 ultrasonically abnormal fetuses.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to assess the application value of chromosome microarray analysis (CMA) for prenatal diagnosis of fetuses with ultrasonic abnormalities. A retrospective study was conducted on 315 fetuses with ultrasonic abnormalities without aneuploidies who received prenatal diagnosis at Meizhou People's Hospital, from October 2022 to December 2023. Fetal specimens obtained by ultrasound guided puncture were detected by CMA analysis with Affymetrix CytoScan 750K array. The detection rate of chromosomal abnormalities in different ultrasonic abnormalities was analyzed. Among the 315 fetuses, 16 (5.08%) were detected with pathogenic/likely pathogenic copy number variants (P/LP CNVs). Three (5.88%) among 51 cases with ultrasound structural abnormalities in multiple organ systems were detected with P/LP CNVs, 5 (6.02%) among 83 cases with a single structural anomaly were detected with P/LP CNVs, and 8 (4.42%) among 181 cases with ultrasonographic soft markers were detected with P/LP CNVs. Compared with conventional karyotyping analysis, CMA can improve the detection of fetal chromosomal abnormalities and provide an effective diagnostic tool for prenatal diagnosis. Chromosomal microarray analysis; Ultrasonic abnormality; Karyotype; Prenatal diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.